HEMOGENYX PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.65 GBX | +4.10% |
|
+0.55% | -28.26% |
| 04-25 | EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout | AN |
| 04-25 | Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 12.98M 17.74M |
|---|---|---|---|---|---|
| Net income 2021 | -5M -6.83M | Net income 2022 | -3M -4.1M | EV / Sales 2021 | - |
| Net cash position 2021 | 6.83M 9.34M | Net Debt 2022 | 890K 1.22M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.85
x | P/E ratio 2022 |
-3.26
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.27% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.10% | ||
| 1 week | +0.55% | ||
| Current month | -6.25% | ||
| 1 month | -7.04% | ||
| 3 months | -38.89% | ||
| 6 months | -22.35% | ||
| Current year | -28.26% |
1 week
1.53
1.70
1 month
1.531.80
Current year
1.537.13
1 year
1.107.13
3 years
1.057.13
5 years
0.9515.39
10 years
0.9515.39
| Managers | Title | Age | Since |
|---|---|---|---|
Alexis Sandler
FOU | Founder | - | 11-12-31 |
| Founder | 59 | 11-12-31 | |
Elina Shrestha
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Redmond
BRD | Director/Board Member | 76 | 17-10-03 |
Marc Feldmann
CHM | Chairman | 79 | 18-04-08 |
| Founder | 59 | 11-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.65 | +4.10% | 1,887,787 |
| 24-04-25 | 1.585 | -1.43% | 5,559,012 |
| 24-04-24 | 1.608 | -1.29% | 5,063,450 |
| 24-04-23 | 1.629 | +0.87% | 4,149,071 |
| 24-04-22 | 1.615 | -1.58% | 5,660,865 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am
More quotes
Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -28.26% | 27.58M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SILF Stock
